Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension

Expert Opinion on Pharmacotherapy
Gary E Sander, Thomas D Giles

Abstract

The fixed-dose combination of nebivolol and valsartan drug has been clinically evaluated and demonstrated to represent a unique combination of nebivolol, a selective β1-adrenoceptor antagonist and a β3-adrenoceptor agonist; β3 receptor activation increases endothelial nitric oxide and produces vasodilation. Valsartan is highly selective angiotensin AT1 receptor blocker and exerts its major pharmacological effect by decreasing angiotensin II-induced vasoconstriction and production of aldosterone. The addition of nebivolol counteracts the effects of increased angiotensin II concentrations resulting from potent AT1 blockade. This review describes a recently completed trial establishing the efficacy of the nebivolol/valsartan combination. This review provides a literature search of pertinent pharmacological and clinical data that describes the mechanisms of both drugs individually and the results of a clinical trial comparing fixed-dose combinations of nebivolol with valsartan as compared with each drug as monotherapy. Fixed-dose combination drugs are intended to improve patient compliance and reduce drug costs, as well as to reduce long-term cardiovascular event rates and block counter-regulatory effects due to monotherapy. The va...Continue Reading

References

Nov 28, 2002·European Journal of Heart Failure·Bernhard R BrehmTeut Risler
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Nov 12, 2003·The New England Journal of Medicine·Marc A PfefferUNKNOWN Valsartan in Acute Myocardial Infarction Trial Investigators
Dec 12, 2003·Journal of Cardiovascular Pharmacology·Annemieke A de GrootStephan L M Peters
Aug 18, 2006·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Renzo M R LombardoStefano De Castro
Jan 15, 2008·Journal of Hypertension·Zahid DhakamIan B Wilkinson
May 21, 2009·Journal of Cardiovascular Pharmacology·George Bakris
Oct 10, 2009·Journal of the American College of Cardiology·Thomas Münzel, Tommaso Gori
May 13, 2010·Current Diabetes Reviews·Angelo M CarellaElisabetta Antonucci
Nov 3, 2010·American Journal of Nephrology·Jasmina VaragicCarlos M Ferrario
Jan 21, 2012·Clinical Cardiology·Ozgür GünebakmazAbdurrahman Oguzhan
Mar 27, 2012·American Journal of Physiology. Heart and Circulatory Physiology·Lixin MaJames R Sowers
Oct 22, 2013·Journal of the American Society of Hypertension : JASH·Charalambos KoumarasAsterios Karagiannis
Jun 3, 2014·Lancet·Bernard Waeber, François Feihl

❮ Previous
Next ❯

Citations

Nov 20, 2018·The Annals of Pharmacotherapy·Dawn BattiseDonald S Nuzum
Feb 25, 2017·Expert Opinion on Pharmacotherapy·Ismail KocyigitTevfik Ecder
Jan 13, 2017·Cellular Signalling·Alessandro Cannavo, Walter J Koch
Oct 17, 2020·Future Cardiology·Sarah J Wang, Gary E Sander

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.